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Preterm deliveryA case of a pregnant woman with symptomatic atrial myxoma
receiving prophylactic use of corticosteroid for preventing fetal
immaturity is described in the article by Giammarco et al. [1].
This case report includes several important issues to be
considered whenever pregnant patients require open-heart
surgeries, such as gestational stage at the time of surgery, safety
of cardiopulmonary bypass (CPB) use for the mother and the fetus,
treatment strategy, and prognosis of the mother and the fetus
depending on gestational stage. We may sometimes have to
manage such difﬁcult situations where we have to appropriately
decide with limited information and clues whether to save the
mother’s life ﬁrst or try to achieve both lives.
There is a basic idea to take into account, according to her
gestational stage, in planning treatment strategy for pregnant
women with cardiac disorders as follows:
#1 when gestational stage is <28 weeks, priority of life is
forwarded to mother’s life.
#2 when gestational stage is between 28 and 32 weeks,
prognostic evaluation of both lives is uncertain and choice of
treatment strategy should be made accordingly.
#3 when gestational stage is >32 weeks, cesarean section/
vaginal delivery and open-heart surgeries usually can be
recommended to save both lives.
As in this case with gestational stage of 32 weeks, the strategy
was naturally deemed to be cesarean section/vaginal delivery and
open-heart surgery immediate after the delivery, and thus CPB use
would be avoided. In fact, reports on the CPB use for pregnant
patients are limited, and among them, John et al. described in
2011 their case series of pregnant patients undergoing open-heart
surgeries (for any cardiac diseases) from the Mayo clinic surgical
database [2]. In this report, median gestational stage was 25 weeks,
including 11 preterm deliveries (6 with less than 33 weeks ofDOI of original article: http://dx.doi.org/10.1016/j.jccase.2015.08.012
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neonatal complications occurred only in those of preterm neonates
(1 intrauterine growth restriction, 7 respiratory distress syndrome,
8 prolonged hospital stay >7 days). Sepehripour [3] and Yuan [4]
summarized in their review articles on evidence regarding the safe
use of CPB in pregnant patients and overall prognosis. According to
those comprehensive analyses of previous publications, the
authors commented that the use of CPB during pregnancy is a
high-risk procedure and associated with relatively high fetal and
maternal mortality. However, in a particular setting where the use
of CPB cannot be avoided to save maternal life, CPB management
was by the use of high-ﬂow, high pressure, pulsatile, and
normothermia, and close monitoring of fetus and uterus (trans-
abdominal/transvaginal ultrasound, etc.) may guide safer control
of maternal and fetal status during open-heart surgery. Yates et al.
reported their experience with 11 pregnant patients undergoing
aortic valve surgery [5], with 0 maternal mortality, and 3 pregnan-
cies resulting in intrauterine demise, even under appropriate
maternal and fetal management during the surgery. Management
of cardiac myxoma during pregnancy, the incidence of which is
low, usually requires meticulous decision-making on the timing of
surgery considering the balance between the risk of embolic events
and the risk of CPB use. The treatment strategy is optimized
according to the circumstance of individual cases, and most of the
reports presented favorable maternal and fetal outcomes probably
because the surgery would be carried out under detailed
assessment and precise planning as a scheduled procedure, and
the operation time and CPB duration would be expected to be short
and have less adverse inﬂuence on the fetal outcome [6,7].
Performing CPB during pregnancy may compromise safety of
fetal life, but on the other hand, placing CPB after delivery may also
result in a great risk of postpartum bleeding due to systemic
heparinization. Hysterectomy is the standard treatment of choice
in this setting, and substantial explanation needs to be given to the
mothers, especially to nulliparous women.
Efﬁcacy of antenatal corticosteroid (ACS) use has been a widely
accepted strategy to lower the risk of complications in preterm
neonates. In the report by Sasaki et al. [8], the impact of ACS in
very-low-birth-weight infants was evaluated and data from the
Japanese neonatal research network database were analyzed,
which revealed that ACS treatment is associated with decreases in
infant mortality and severe morbidity, and decrease in respiratory
distress (RDS) was especially observed in the infants with vaginal
delivery. In the review by Falah et al. [9], beneﬁts of ACS in clinical
use (reduction in mortality, RDS, intraventricular hemorrhage, etc.)
for a wide range of preterm conditions like gestational age and ACSs reserved.
Editorial / Journal of Cardiology Cases 13 (2016) 70–71 71pharmacokinetics/pharmacodynamics were described. Even
though most of the previous reports on cardiac surgery in
pregnancy mainly discussed safer management of CPB and
maternal/fetal prognosis, few have commented on active chal-
lenges to prevent preterm fetal complications and to control the
timing of delivery/the surgery to mothers, including ACS treatment
as a part of preparation to decrease feto-neonatal complications. As
is generally known, as well as cited in this article or in the reference
[1], RDS of the preterm newborns is one of the predominant
complications in preterm neonates, and possible prophylactic
measurements against such complications need to be taken into
account, especially those in the gestational stage around 30 weeks,
expecting to obtain the best outcome for both the mother and the
infants. Continuous effort to accumulate such experiences is
expected.
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